Canaccord raised the firm’s price target on Atara Biotherapeutics (ATRA) to $25 from $17 and keeps a Buy rating on the shares. The firm said they ...

The U.S. Food and Drug Administration (FDA) has accepted the filing of Atara’s Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Atara Biotherapeutics, Inc. before investing. In this article, we go over a few ...

Atara Biotherapeutics Research Center in Thousand Oaks. (courtesy photo) Thousand Oaks-based Atara Biotherapeutics is putting the fate of its lead treatment back into the hands of the U.S. Food and ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA approval on the horizon. Pierre Fabre Laboratories has assumed global ...

The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Canaccord Genuity on March 11, 2025. The analyst firm set a price target for $17.00 expecting ATRA to rise to within 12 ...

Revenue: US$128.9m (up by US$120.4m from FY 2023). Net loss: US$85.4m (loss narrowed by 69% from FY 2023). US$11.41 loss per share (improved from US$65.18 loss in FY 2023). Revenue exceeded analyst ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of ...

Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara revealed in ...